GRI Bio (GRI) Net Equity Issued and Repurchased (2023 - 2026)

GRI Bio's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $6.8 million for Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased rose 89.15% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $23.4 million (up 1862.53% YoY), while the FY2025 annual figure was $13.0 million, up 260.71% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $6.8 million, down from $10.4 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $12.2 million in Q2 2023, with the low at -$12.2 million in Q4 2023.
• The 4-year median for Net Equity Issued and Repurchased is $3.6 million (2025), against an average of $2.5 million.
• The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased sank 92.16% in 2024, then jumped 546.04% in 2025.
• GRI Bio's Net Equity Issued and Repurchased stood at -$12.2 million in 2023, then jumped by 113.19% to $1.6 million in 2024, then surged by 546.04% to $10.4 million in 2025, then sank by 34.68% to $6.8 million in 2026.
• Business Quant data shows GRI's Net Equity Issued and Repurchased at $6.8 million in Q1 2026, $10.4 million in Q4 2025, and $1.6 million in Q3 2025.